A Phase II Trial of Niraparib in Patients with Advanced Pancreatic Cancer Harboring Pathogenic Variants in <i>ATM</i> , <i>BRCA1</i> , <i>BRCA2</i> , <i>PALB2</i> , and <i>CHEK2</i>
Niraparib demonstrated clinically meaningful benefit in a subset of patients. The prolonged PFS observed in patients with biallelic ATM loss warrants further investigation.
Authors
- Ahmed Rattani (ORCID: https://orcid.org/0000-0002-1058-7314)
- Matthew B.B. Yurgelun (ORCID: https://orcid.org/0000-0002-6184-9273)
- Anuj Patel (ORCID: https://orcid.org/0000-0002-7045-6957)
- Zoltán Szállási (ORCID: https://orcid.org/0000-0001-5395-7509)
- Brandon M. Huffman (ORCID: https://orcid.org/0000-0002-0768-3145)
- Kalindi T Parmar
- Douglas A. Rubinson (ORCID: https://orcid.org/0000-0002-5337-5231)
- Brian M. Wolpin (ORCID: https://orcid.org/0000-0002-0455-1032)
- Marios Giannakis (ORCID: https://orcid.org/0000-0001-9012-6982)
- Mingyang Cai (ORCID: https://orcid.org/0009-0009-3579-9784)
- Jonathan Andrew Nowak (ORCID: https://orcid.org/0000-0002-0943-7407)
- Andrea C. Enzinger (ORCID: https://orcid.org/0000-0001-7502-8081)
- Benjamin L. Schlechter (ORCID: https://orcid.org/0000-0002-1529-3278)
- Andrea J. Bullock (ORCID: https://orcid.org/0000-0001-7143-0225)
- J. Crowdis
- Leah H. Biller (ORCID: https://orcid.org/0000-0001-7386-7121)
- Yvonne Li (ORCID: https://orcid.org/0000-0002-1741-1995)
- Caroline Weipert (ORCID: https://orcid.org/0000-0002-0069-882X)
- Nadine Jackson
- Andrew J. Aguirre (ORCID: https://orcid.org/0000-0002-0701-6203)
- Bose Kochupurakkal (ORCID: https://orcid.org/0000-0001-8929-3070)
- Elizabeth Andrews (ORCID: https://orcid.org/0000-0003-1131-5983)
- Alan D D'Andrea
- Leigh Culnane
- Kaitlyn Ramsey
- Geoffrey Shapiro
- Kimmie Ng
- Harshabad Singh
- Srivatsan Raghavan
- Jefferey W. Clark
- James M. Cleary
- Miklos Diossy
- Mary Linton Peters
- Helen Lam
- Sarah C. Loeb
- Leonard Vonk
- Huy Nguyen
Institutions
- Semmelweis University (HU)
- Broad Institute (US)
- Brigham and Women's Hospital (US)
- Boston Children's Hospital (US)
- Beth Israel Deaconess Medical Center (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Guardant (United States) (US)
- Dana-Farber Cancer Institute (US)
- Danish Cancer Society (DK)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2026-02-13
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-3766
- Citations
- 1
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 24.20